Adaptive Biotechnologies (ADPT) Income from Continuing Operations (2018 - 2026)

Adaptive Biotechnologies has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 20015000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 20015000.0, up 32.9% year-over-year; the trailing twelve-month figure through Mar 2026 was 49642000.0 (up 65.01% YoY), and the FY2025 annual result was 59457000.0, up 62.75% from the prior year.
• Income from Continuing Operations came in at 20015000.0 for Q1 2026 at Adaptive Biotechnologies, down from 13579000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 9545000.0 in Q3 2025 to a low of 69467000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 45319000.0 (2022), against an average of 39102294.12.
• Across the five-year window, Income from Continuing Operations plunged 72.94% in 2023 and jumped 129.74% in 2025, its largest moves.
• Adaptive Biotechnologies' Income from Continuing Operations stood at 40169000.0 in 2022, then slumped by 72.94% to 69467000.0 in 2023, then soared by 51.46% to 33717000.0 in 2024, then surged by 59.73% to 13579000.0 in 2025, then plunged by 47.4% to 20015000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 20015000.0 (Q1 2026), 13579000.0 (Q4 2025), and 9545000.0 (Q3 2025), per Business Quant data.